http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yang, Huai,Liu, Shirong,Li, Yide,Xu, Han Springer Japan 2018 Ecological research Vol.33 No.2
<P><B>Abstract</B></P><P>Accurate estimations of soil greenhouse gas (GHG) fluxes in tropical montane rainforests are critical for assessing the role of tropical forests in influencing global climate change. This research aimed to determine the diurnal variation in soil GHG fluxes and understand the effects of forest canopy gaps on GHG fluxes, and their major controlling factors. The diurnal fluxes of soil carbon dioxide (CO<SUB>2</SUB>), nitrous oxide (N<SUB>2</SUB>O) and methane (CH<SUB>4</SUB>) inside and outside three forest canopy gaps in a tropical montane rainforest were measured with a closed static chamber system in June 2015. The main results are as follows. (1) There was an obvious single‐peak daily variation of soil GHG fluxes. (2) The averaged soil CO<SUB>2</SUB>, N<SUB>2</SUB>O and CH<SUB>4</SUB> fluxes of the whole day were closest to the daily average emission fluxes at 9:00 and 12:00 for CO<SUB>2</SUB>, 6:00 and 9:00 for N<SUB>2</SUB>O, and 9:00 and 12:00 for CH<SUB>4</SUB>, respectively. (3) Soil CO<SUB>2</SUB> and N<SUB>2</SUB>O emissions (positive values) and CH<SUB>4</SUB> uptake (negative values) were higher inside gaps than outside. (4) There were stronger exponential relationships between soil CO<SUB>2</SUB> and N<SUB>2</SUB>O emissions and temperature inside gaps than outside, and there was a stronger quadratic relationship between CH<SUB>4</SUB> uptake and temperature outside gaps than inside. However, significant relationships between soil CO<SUB>2</SUB> (or CH<SUB>4</SUB>) and soil moisture only occurred inside gaps (<I>P</I> < 0.01). There were clear diurnal variations and significant effects of gaps on soil CO<SUB>2</SUB>, N<SUB>2</SUB>O and CH<SUB>4</SUB> fluxes. Our study indicated that understanding the different diurnal variations of soil CO<SUB>2</SUB>, N<SUB>2</SUB>O and CH<SUB>4</SUB> fluxes inside and outside canopy gaps could improve the accurate evaluation of soil GHG fluxes in tropical montane rainforests under a changing climate.</P>
Magnetic domain observations of (Tb0.3Dy0.7)Fe1.95 alloys
Li Kuoshe,Fang Yikun,Zhang Shirong,Yu Dunbo,Han Baoshan 한양대학교 세라믹연구소 2006 Journal of Ceramic Processing Research Vol.7 No.2
The magnetic domain structures of (Tb0.3Dy0.7)Fe1.95 alloys were investigated using scanning probe atomic and magnetic force microscopies. Results demonstrate that the specimen surface presented corrugated and spiked domain configurations interpreted in terms of surface closure domains in cubic magnetic materials after the specimen was annealed at 673 K for 2 h in an ultra-high vacuum of 5×10−5 Pa. However, a thin soft magnetic Fe layer appeared on the specimen surface after annealing at 723 K for 2 h in a relatively high vacuum of 5×10−3 Pa. As a result, the demagnetized energy in the specimen surface is largely reduced and the interior magnetic domain configurations of the specimen are observed. The results maybe provide an approach for detecting the interior magnetic domain structures of TbDyFe alloys or other cubic magnetic materials.
Kan Yonemori,Keiichi Fujiwara,Kosei Hasegawa,Mayu Yunokawa,Kimio Ushijima,Shiro Suzuki,Ayumi Shikama,Shinichiro Minobe,Tomoka Usami,김재원,김병기,Peng-Hui Wang,Ting-Chang Chang,Keiko Yamamoto,Shirong Han,Jo 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.2
Objective: In the global phase 3 Study 309/KEYNOTE-775 (NCT03517449) at the first interimanalysis, lenvatinib+pembrolizumab significantly improved progression-free sur vival (PFS),overall sur vival (OS), and objective response rate (ORR) versus treatment of physician’schoice chemotherapy (TPC) in patients with previously treated advanced/recurrentendometrial cancer (EC). This explorator y analysis evaluated outcomes in patients enrolledin East Asia at the time of prespecified final analysis. Methods: Women ≥18 years with histologically confirmed advanced, recurrent, or metastaticEC with progressive disease after 1 platinum-based chemotherapy (2 if 1 given in neoadjuvant/adjuvant setting) were enrolled. Patients were randomized 1:1 to lenvatinib 20 mg orallyonce daily plus pembrolizumab 200 mg intravenously ever y 3 weeks (≤35 cycles) or TPC(doxorubicin or paclitaxel). Primar y endpoints were PFS per RECIST v1.1 by blindedindependent central review and OS. No alpha was assigned for this subgroup analysis. Results: Among 155 East Asian patients (lenvatinib+pembrolizumab, n=77; TPC, n=78),median follow-up time (data cutoff: March 1, 2022) was 34.3 (range, 25.1–43.0) months. Hazard ratios (HRs) with 95% confidence inter vals (CIs) for PFS (lenvatinib+pembrolizumabvs. TPC) were 0.74 (0.49–1.10) and 0.64 (0.44–0.94) in the mismatch repair proficient(pMMR) and all-comer populations, respectively. HRs (95% CI) for OS were 0.68 (0.45–1.02)and 0.61 (0.41–0.90), respectively. ORRs were 36% with lenvatinib+pembrolizumab and 22%with TPC (pMMR) and 39% and 21%, respectively (all-comers). Treatment-related adverseevents occurred in 97% and 96% (grade 3–5, 74% and 72%), respectively. Conclusion: Lenvatinib+pembrolizumab provided clinically meaningful benefit withmanageable safety compared with TPC, supporting its use in East Asian patients withpreviously treated advanced/recurrent EC. Trial Registration: ClinicalTrials.gov Identifier: NCT03517449